» Articles » PMID: 39696678

Exploring Glioma Heterogeneity Through Omics Networks: from Gene Network Discovery to Causal Insights and Patient Stratification

Overview
Journal BioData Min
Publisher Biomed Central
Specialty Biology
Date 2024 Dec 19
PMID 39696678
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas are primary malignant brain tumors with a typically poor prognosis, exhibiting significant heterogeneity across different cancer types. Each glioma type possesses distinct molecular characteristics determining patient prognosis and therapeutic options. This study aims to explore the molecular complexity of gliomas at the transcriptome level, employing a comprehensive approach grounded in network discovery. The graphical lasso method was used to estimate a gene co-expression network for each glioma type from a transcriptomics dataset. Causality was subsequently inferred from correlation networks by estimating the Jacobian matrix. The networks were then analyzed for gene importance using centrality measures and modularity detection, leading to the selection of genes that might play an important role in the disease. To explore the pathways and biological functions these genes are involved in, KEGG and Gene Ontology (GO) enrichment analyses on the disclosed gene sets were performed, highlighting the significance of the genes selected across several relevent pathways and GO terms. Spectral clustering based on patient similarity networks was applied to stratify patients into groups with similar molecular characteristics and to assess whether the resulting clusters align with the diagnosed glioma type. The results presented highlight the ability of the proposed methodology to uncover relevant genes associated with glioma intertumoral heterogeneity. Further investigation might encompass biological validation of the putative biomarkers disclosed.

References
1.
Liu X, Zhang L, Wu J, Zhou L, Ren Y, Yang W . Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma. PLoS One. 2013; 8(11):e81345. PMC: 3841121. DOI: 10.1371/journal.pone.0081345. View

2.
Laurini E, Marson D, Fermeglia A, Aulic S, Fermeglia M, Pricl S . Role of Rad51 and DNA repair in cancer: A molecular perspective. Pharmacol Ther. 2020; 208:107492. DOI: 10.1016/j.pharmthera.2020.107492. View

3.
Liao G, Li X, Zeng S, Liu C, Yang S, Yang L . Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal. 2018; 16(1):57. PMC: 6134757. DOI: 10.1186/s12964-018-0266-6. View

4.
Tao B, He H, Shi X, Wang C, Li W, Li B . Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci. 2013; 20(5):717-20. DOI: 10.1016/j.jocn.2012.03.050. View

5.
Huang S, Xiao J, Wu J, Liu J, Feng X, Yang C . Tizoxanide Promotes Apoptosis in Glioblastoma by Inhibiting CDK1 Activity. Front Pharmacol. 2022; 13:895573. PMC: 9174573. DOI: 10.3389/fphar.2022.895573. View